Upon binding to BCL2, the BCL2 inhibitor (BCL2i) venetoclax reduces the binding affinity of the anti-apoptotic protein with BAX, thus promoting apoptosis in CLL cells (Figure 1) [11]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.